Immunotherapeutically-targeting IDO1 in Pediatric High-grade Glioma

Email Principal Investigator
Completed
Data
HGG

About this

Project

Cancer Immunotherapy is a therapy which uses the patient’s own immune system to destroy tumors. This strategy is considered particularly promising for patients with high-grade pediatric brain cancer, whose survival rate is currently 10-15% despite use of aggressive surgical and radiation treatments. Immune cells are capable of the destruction of glioblastoma (GBM), but research into adults with GBM has shown a direct relationship between heightened levels of enzymes that suppress the immune system and a lowered survival rate. The impact of levels of these same enzymes in patients with pediatric brain cancer has yet to be explored. Using the Pediatric Brain Tumor Atlas, researchers seek to address this knowledge gap alongside other immune system analysis.

Ask The

Scientists

Ask the scientists

What are the goals of this project?

Previous studies into adult patients with GBM have shown a relationship between increased expression of enzymes that suppress the immune system and a lowered survival rate. Researchers are interested in exploring this connection in pediatric brain tumors.

What is the impact of this project?

A greater understanding of immune system response in pediatric brain tumors could lead to better therapies, including cancer immunotherapy, which uses a patient’s own immune system to attack the tumor. This is especially impactful for patients with high grade tumors that are unresponsive to radiation and surgical interventions.

Why is the CBTN request important to this project?

Access to the Pediatric Brain Tumor Atlas will allow researchers to test their hypothesis to fill the knowledge gap between adult and pediatric brain tumors and the feasibility of cancer immunotherapy as a treatment option.

Specimen Data

Access to the Pediatric Brain Tumor Atlas will allow researchers to test their hypothesis to fill the knowledge gap between adult and pediatric brain tumors and the feasibility of cancer immunotherapy as a treatment option.

Explore the data in these informatics portals

Cavativa-Logo.png